Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $301 to $310.